Two MD Anderson faculty named to Institute of Medicine

October 20, 2014

"Two leaders at The University of Texas MD Anderson Cancer Center have been elected to the Institute of Medicine (IOM) of the National Academies in recognition of their contributions to medical science and health care.

Election of Guillermina Lozano, Ph.D., chair of the department of genetics, and David Piwnica-Worms, M.D., Ph.D., chair of the department of cancer systems imaging by members of the elite institution was announced today by the IOM.

"Membership in the Institute of Medicine is powerful recognition by outstanding peers of the impact Dr. Lozano and Dr. Piwnica-Worms have had as researchers and leaders in advancing our understanding and treatment of cancer," said Ethan Dmitrovsky, M.D., provost and executive vice president at MD Anderson.

"Their election demonstrates the remarkable achievements of Guillermina Lozano, a recognized leader in the field of cancer genetics and David Piwnica-Worms, an exceptional scientist who excels at translating molecular research to the clinic where it directly helps our patients," Dmitrovsky said.

Membership in the IOM recognizes people who have demonstrated outstanding professional achievement and commitment to service.

Lozano, a leader in deciphering the physiological relevance of the p53 tumor suppressor pathway, discovered the importance of p53 inhibitors, Mdm2 and Mdm4, in development and tumorigenesis. She illuminated cell cycle arrest and senescence as wild-type p53 tumor suppressive mechanisms, and defined mutant forms of p53 activities in tumorigenesis.

Piwnica-Worms was a founder of the field of molecular imaging. He pioneered strategies with genetically encoded luminescent reporters, PET reporters, and activatable peptides to enable visualization of cell biology, signaling pathways, protein processing and drug action within cells and living animals in vivo, as well as translating these into the clinic.

With the addition of Lozano and Piwnica-Worms MD Anderson has nine IOM members: Waun Ki Hong, M.D., professor of thoracic head and neck medical oncology; Helen Piwnica-Worms, Ph.D., vice provost for science; President Ronald DePinho, M.D.; John Mendelsohn, M.D., former president and director of the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy; Ellen Gritz, Ph.D., chair of behavioral science; James Allison, Ph.D., chair of immunology; and Lynda Chin, M.D., chair of genomic medicine and scientific director of the Institute for Applied Cancer Science.
-end-
Established in 1970, the IOM also serves an important advisory role, with panels of members volunteering to study important issues in medical science, health care and public health. IOM projects during the past year include studies of the benefits of including physical activity in the school environment, direct health outcomes of sodium intake, regional variations in Medicare spending, child abuse and neglect in the U.S., improved delivery of cancer care, the commercial sexual exploitation and sex trafficking of minors in the U.S., post-deployment needs of Iraq and Afghanistan service members, gun violence research priorities and the problem of illegitimate and substandard medications. Editors' Note: This release is being resent. An earlier version contained an incorrect listing of all Institute of Medicine members currently at MD Anderson Cancer Center.

University of Texas M. D. Anderson Cancer Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.